Lifting Lids: Update on the Medical Treatment of Acquired Blepharoptosis (Archived CME Webcast)
This educational activity has expired. You will not be able to claim credit for this activity.
Activity Description and Purpose
Blepharoptosis is a condition that affects millions worldwide, but it is often overlooked and undertreated. Until recently, surgical procedures were the most appropriate treatments to correct ptotic eyelids, leaving both clinicians and patients with few less-invasive treatment solutions. A topical drop is now available to treat forms of acquired ptosis. The following webcast features select presentations from a series of live webinars on the diagnosis and treatment of blepharoptosis. A review of clinical data on both the on-label treatment and several off-label treatments for ptosis as well as many real-world cases of patients with ptosis are included to help clinicians gain comfort and confidence in their ability to optimally treat their patients.
This educational activity is intended for ophthalmologists.
After completing this activity, participants will be better able to:
- Describe the pathophysiology of blepharoptosis
- Review clinical data on the pharmacologic treatment options for blepharoptosis
- Identify the appropriate treatment course for a variety of patients with acquired blepharoptosis
|Wendy W. Lee, MD, MS (Chair)|
Professor of Clinical Ophthalmology and Dermatology
Oculofacial Plastic & Reconstructive Surgery, Orbit, and Oncology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
|John P. Fezza, MD|
Center for Sight
Andrew R. Harrison, MD
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
John P. Fezza, MD, receives royalties from Visant Medical, Inc; is a consultant for Allergan and Revance Therapeutics, Inc; is on the speakers bureau for Allergan and Revance Therapeutics, Inc; receives fees for non-CME/CE services from Osmotica Pharmaceuticals plc; and has ownership interest (stocks) in Visant Medical, Inc.
Andrew R. Harrison, MD, is a consultant for Horizon Therapeutics plc and Osmotica Pharmaceuticals plc.
Wendy W. Lee, MD, MS, is a consultant for Allergan, Bausch & Lomb Incorporated, Evolus, Galderma, Horizon Therapeutics plc, Mallinckrodt, Osmotica Pharmaceuticals plc, and Revance Therapeutics, Inc.
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from RVL Pharmaceuticals, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at firstname.lastname@example.org.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or RVL Pharmaceuticals, Inc.
This CME activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 256